Eylea Approved for the Treatment of Diabetic Retinopathy
The Food and Drug Administration (FDA) has approved Eylea (aflibercept; Regeneron) for the treatment of diabetic retinopathy.
Ophthalmic Disorders
Xeomin Approved as First-Line Treatment for Blepharospasm
The FDA has approved Xeomin (incobotulinumtoxinA; Merz) as a first-line treatment for blepharospasm in adults.
Longer Duration of Statin Use Linked to Lower Risk for Glaucoma
Self-reported high cholesterol levels without statin use tied to higher glaucoma risk
New Drug Product: Dexycu
This slideshow reviews drug information for Dexycu. Click here for the complete Dexycu monograph.
Avaclyr Approved for the Treatment of Acute Herpetic Keratitis
The Food and Drug Administration (FDA) has approved Avaclyr (acyclovir ophthalmic ointment; Fera Pharmaceuticals) 3% for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.
Lotemax SM Now Available for Post-Op Ocular Pain and Inflammation
Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% has been made available by Bausch + Lomb for the treatment of postoperative inflammation and pain following ocular surgery.
First-of-its-Kind Contact Lens With Faster Light Adaptation Coming Soon
Johnson & Johnson announced the coming launch of Acuvue Oasys with Transitions Light Intelligent Technology, a first-of-its-kind photochromic contact lens that adapts to changing light. The lens was initially cleared by the Food and Drug Administration (FDA) in April 2018. The FDA based their approval on scientific evidence including a clinical study of 24 patients…
Dexycu Now Available for Treatment of Post-Op Ocular Inflammation
EyePoint announced the launch of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation after cataract surgery.
Rocklatan Approved to Reduce IOP in Patients With Open-Angle Glaucoma or Ocular Hypertension
The Food and Drug Administration (FDA) has approved Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution; Aerie) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Lotemax SM Approved for Post-Op Inflammation, Pain Following Ocular Surgery
The Food and Drug Administration (FDA) has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery.
